← Leaderboards
Craig Patrick Ramirez
Tezcat Laboratories Llc
$3,645,136
Attributed
$4,317,521
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,317,521 · 4
By mechanism
R44$3,308,943 · 2
R41$1,008,578 · 2
Top collaborators
- Dafna Bar-Sagi3 shared
- Shohei Koide2 shared
- Gareth John Morgan1 shared
Most similar at Tezcat Laboratories Llc
Same institution · by research overlap
- Gareth John Morgan$5,963,595
Others in their field
Other Emerging Leaders on “Drug Candidate”
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn$46,710,255
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
- Ryan Cirz · Revagenix, Inc.$22,711,751
- Alan D. Palkowitz · Indiana University Indianapolis$17,630,798
Research focus
Drug CandidateClinical TrialsTumorPharmaceutical PreparationsBiotechnologySafetyProgramsSmall Business Technology Transfer ResearchMutantCytotoxicProtocols DocumentationSmall Business Innovation Research GrantFda ApprovedResearch PersonnelCommercializationInnovationMalignant NeoplasmsFirst-In-HumanProteinsLeadCancer CellNeoplastic CellCharacteristicsIn Vivo
Grant awards (7)
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.$1,113,257
R44 · FY2025 · CA · contact PI
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$205,593
R44 · FY2025 · CA · contact PI
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$928,011
R44 · FY2024 · CA · contact PI
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$1,062,082
R44 · FY2023 · CA · contact PI
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.$209,986
R41 · FY2022 · CA · contact PI
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.$398,715
R41 · FY2021 · CA · contact PI
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$399,877
R41 · FY2020 · CA · contact PI